Scleroderma

HomePatientsLung Disease Week at the ATS2015 ▶ Scleroderma
Scleroderma Week

Scleroderma Week

Welcome Message

It is our pleasure to welcome you to the Scleroderma week at the ATS.  Scleroderma is an autoimmune disease that can affect multiple organ systems.  While the term Scleroderma refers to thickening and hardening of the skin, pulmonary involvement is common (>70% of patients with Scleroderma have pulmonary involvement) and a significant cause of morbidity and mortality. 

The pulmonary involvement in Scleroderma can manifest in several forms including interstitial lung disease and pulmonary hypertension.  Additionally, esophageal involvement is common and esophageal motility issues can predispose patients to aspiration of stomach contents into the lungs.  Although several treatment options for pulmonary hypertension have been established, effective treatment options for interstitial lung disease are still limited.  Cyclophosphamide has been the most thoroughly studied medication, but the use of other agents such as azathioprine, mycophenolate and adjuvant glucocorticoids have been described.  Alternative treatment options such as rituximab, bosentan, pirfenidone and hematopoietic stem cell transplant are currently being explored. 

Many ATS members are involved with scleroderma in direct patient care as well as ongoing research efforts.  With our PAR partner, Kerri Connolly of the Scleroderma Foundation, we hope to continue to increase awareness of scleroderma for clinicians, researchers and patients alike.  We hope that the materials provided this week will serve as a useful resource in this regard.

 

Robin Deterding, MD

Ganesh Raghu, MD          
Adjunct Professor, Laboratory Medicine
Division of Pulmonary and Critical Care Medicine
Director, Interstitial Lung Disease/Sarcoidosis/Pulmonary Fibrosis Program
University of Washington, School of Medicine

Donna Appell, RN

Laurence Ho, MD
Clinical Assistant Professor
Division of Pulmonary and Critical Care Medicine
University of Washington, School of Medicine

Kerri Connolly

Kerri Connolly
Director of Programs and Services
Scleroderma Foundation
Member, ATS Public Advisory Roundtable

 

ATS Scleroderma Foundation Partner
Scleroderma Foundation

image

 

The Scleroderma Foundation is the national organization for people with scleroderma and their families and friends. It was formed January 1, 1998, by a merger between the West Coast-based United Scleroderma Foundation and the East Coast-based Scleroderma Federation. Their three-fold mission is based on furthering support, education, and research for scleroderma and related diseases.